NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides (NYSE:NNVC) announces a corporate presentation at the Spartan Capital Investors Conference 2024 on November 4, featuring their lead drug candidate NV-387. The presentation will highlight NV-387's completion of Phase I clinical trials and its demonstrated antiviral activity against multiple viruses including Influenza, RSV, COVID, and MPox/Smallpox. The company notes that NV-387 targets a market estimated at $2.5 to $4.3 billion for RSV alone, with the overall market for targeted indications projected to exceed $10 billion by 2027.
NanoViricides (NYSE:NNVC) annuncia una presentazione aziendale alla Spartan Capital Investors Conference 2024 il 4 novembre, incentrata sul loro principale candidato farmacologico NV-387. La presentazione metterà in evidenza il completamento della fase I degli studi clinici di NV-387 e la sua dimostrata attività antivirale contro diversi virus, tra cui Influenza, RSV, COVID e MPox/Varicella. L'azienda sottolinea che NV-387 punta a un mercato stimato tra i 2,5 e i 4,3 miliardi di dollari solo per RSV, con il mercato complessivo per le indicazioni mirate che si prevede supererà i 10 miliardi di dollari entro il 2027.
NanoViricides (NYSE:NNVC) anuncia una presentación corporativa en la Spartan Capital Investors Conference 2024 el 4 de noviembre, destacando su principal candidato a fármaco NV-387. La presentación resaltará la finalización de los ensayos clínicos de Fase I de NV-387 y su actividad antiviral demostrada contra múltiples virus, incluidos Influenza, RSV, COVID y MPox/Variola. La empresa señala que NV-387 tiene como objetivo un mercado estimado en 2.5 a 4.3 mil millones de dólares solo para RSV, con el mercado total para indicaciones específicas proyectado para superar los 10 mil millones de dólares para 2027.
나노바이러스 (NYSE:NNVC)는 11월 4일 스파르탄 캐피탈 투자 컨퍼런스 2024에서 자사의 주요 약물 후보 NV-387에 대한 기업 발표를 공지했습니다. 이번 발표에서는 NV-387의 1상 임상시험 완료와 인플루엔자, RSV, COVID, MPox/천연두 등 여러 바이러스에 대한 항바이러스 활성에 대해 강조할 것입니다. 회사는 NV-387이 RSV 단독으로 25억에서 43억 달러로 추정되는 시장을 겨냥하고 있으며, 목표 적응증에 대한 전체 시장이 2027년까지 100억 달러를 초과할 것으로 예상하고 있다고 언급했습니다.
NanoViricides (NYSE:NNVC) annonce une présentation d'entreprise lors de la Spartan Capital Investors Conference 2024 le 4 novembre, mettant en avant leur principal candidat médicament NV-387. La présentation mettra en lumière l'achèvement des essais cliniques de phase I de NV-387 et son activité antivirale démontrée contre plusieurs virus, y compris la grippe, le RSV, le COVID et le MPox/variole. L'entreprise souligne que NV-387 cible un marché estimé entre 2,5 et 4,3 milliards de dollars rien que pour le RSV, le marché global pour les indications ciblées devant dépasser les 10 milliards de dollars d'ici 2027.
NanoViricides (NYSE:NNVC) kündigt eine Unternehmenspräsentation auf der Spartan Capital Investors Conference 2024 am 4. November an, die sich auf ihren Hauptkandidaten NV-387 konzentriert. Die Präsentation wird den Abschluss der Phase-I-Studien für NV-387 und seine nachgewiesene antivirale Aktivität gegen mehrere Viren, einschließlich Influenza, RSV, COVID und MPox/Pocken, hervorheben. Das Unternehmen weist darauf hin, dass NV-387 auf einen Markt abzielt, der auf 2,5 bis 4,3 Milliarden Dollar für RSV allein geschätzt wird, wobei der Gesamtmarkt für gezielte Indikationen bis 2027 voraussichtlich 10 Milliarden Dollar übersteigen wird.
- NV-387 successfully completed Phase I clinical trials
- Drug candidate shows broad-spectrum antiviral activity against multiple diseases
- Target market size projected to exceed $10 billion by 2027
- RSV market alone estimated at $2.5-4.3 billion
- None.
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held at the Pierre Hotel in New York City.
Event | The Spartan Capital Investors Conference 2024 |
Day & Date | Monday, November 4, 2024 |
Location | The Pierre Hotel, New York, NY, USA. |
Talk Title | Revolutionizing Antiviral Treatments, Phase 2-Ready, Broad-Spectrum Lead Drug NV-387 Addresses a |
Presenter | Anil R. Diwan, PhD, President & Exec. Chairman, NanoViricides, Inc. |
Track | Collition Room |
Time | 09:45 to 10:00 |
Dr. Diwan will discuss the revolutionary broad-spectrum antiviral drug candidate NV-387, that is enabled by the nanoviricides technology platform. NV-387 has successfully completed Phase I clinical trial.
NV-387 has shown strong antiviral activity, with substantial superiority to existing drugs, against a number of viral diseases in animal models. These include Influenza, RSV, COVID, Influenza, and MPox/Smallpox related animal models.
The overall market size for these indications is anticipated to be more than
About Spartan Capital Investor Conference 2024
The conference, organized in partnership with B2i Digital, a leading digital marketing firm specializing in investor communications, will feature presentations from over 30 carefully selected companies. The event will include panel discussions, one-on-one meetings, and networking sessions to maximize interactions between investors and presenters.
For more information about the conference and registration details, please visit Spartan Capital's conference page.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on accesswire.com
FAQ
What is the current development stage of NanoViricides (NNVC) NV-387 drug?
What is the market potential for NanoViricides (NNVC) NV-387?
When is NanoViricides (NNVC) presenting at the Spartan Capital Investors Conference 2024?
